learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Search
forLearn
5 / 801 resultslearn Fexofenadine
learn dl-alpha-tocopherol
learn phenoxyethanol
learn ascorbic acid
Research
5 / 1000+ results
research Association of 5-α reductase inhibitors and sexual dysfunction: A RADAR report
Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
research Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
EGFR-TKIs can cause significant skin, nail, and organ side effects.
research Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
Statins may be linked to reproductive organ conditions, and their risks should be monitored.
research Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases
Finasteride has a higher risk of reproductive side effects than minoxidil.
research Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
Finasteride use may increase suicidality risk, especially in young men.
Community Join
5 / 1000+ resultscommunity FDA Policy Shift Explained: What It Actually Means for PP405, VDPHL-01, Breezula and Hair Loss Drug Timelines
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
community FDA approves Cassiopea's WINLEVI (CB-03-01, 1% formulation) for Acne
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
community US FDA will now default to only one clinical trial for drug applications, will this accelerate the release of PP405 and other drugs in clinical trials?
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
community New warning by FDA on topical finasteride
The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.
community Alright so FDA better approve PP405 as fast as they approved covid vaccine
PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.